Ligand Pharmaceuticals (LGND) Operating Leases (2019 - 2026)

Ligand Pharmaceuticals has disclosed Operating Leases across 8 years of filings, most recently posting $4.0 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $4.0 million, up 399.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.0 million (up 399.12% YoY), and the FY2025 annual result was $4.2 million, down 41.24% from the prior year.
• Operating Leases came in at $4.0 million for Q1 2026 at Ligand Pharmaceuticals, down from $4.2 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $34.9 million in Q3 2022 to a low of $800000.0 in Q1 2025.
• The 5-year median for Operating Leases is $6.3 million (2024), against an average of $9.9 million.
• Across the five-year window, Operating Leases jumped 467.76% in 2022 and plunged 84.59% in 2025, its largest moves.
• Ligand Pharmaceuticals' Operating Leases stood at $10.3 million in 2022, then slumped by 40.17% to $6.2 million in 2023, then gained by 15.69% to $7.2 million in 2024, then sank by 41.24% to $4.2 million in 2025, then dropped by 5.02% to $4.0 million in 2026.
• The last three Operating Leases figures came in at $4.0 million (Q1 2026), $4.2 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.